AXSOME THERAPEUTICS, INC. (AXSM) FY2026 Q2 P&L / Income Statement

AXSOME THERAPEUTICS, INC. (AXSM) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

218,375,000 US dollars

Cost of revenue (calculated)

13,564,000 US dollars

Gross profit (calculated)

204,811,000 US dollars

Operating expenses (calculated)

254,457,000 US dollars

Loss from operations

negative 49,646,000 US dollars

Other income (expense), net (calculated)

negative 1,540,000 US dollars

Loss before income taxes

negative 51,186,000 US dollars

Income tax benefit (expense)

128,000 US dollars

Net loss

negative 51,314,000 US dollars

Royalty and Milestone Revenue - Outside of the United States

2,020,000 US dollars

Product Sales - UNITED STATES

215,367,000 US dollars

Product Sales - Outside of the United States

988,000 US dollars

Cost of revenue (excluding amortization and depreciation)

13,564,000 US dollars

Research and development

46,227,000 US dollars

Selling, general and administrative

208,137,000 US dollars

Gain in fair value of contingent consideration

negative 1,496,000 US dollars

Intangible asset amortization

1,589,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.